Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2010-12-17 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
Director's Dealing 2010
Director's Dealing
2010-12-17 English
Regulatory Filings 2010
Regulatory Filings
2010-12-17 English
Proxy Solicitation & Information Statement 2010
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a joint proxy statement/prospectus related to a merger between NeoStem, Inc. and Progenitor Cell Therapy, LLC. It includes detailed information about the merger agreement, voting proposals for stockholders and members, risk factors, board recommendations, and other merger-related disclosures. The presence of voting proposals and detailed merger terms indicates this is a proxy solicitation document designed to inform shareholders and request their votes on the merger and related corporate actions. The document is not a full annual report, earnings release, or other financial report, but rather a solicitation for shareholder approval of merger-related matters. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2010-12-16 English
Merger & Acquisition 2010
Merger & Acquisition Classification · 100% confidence The document is a Form S-4/A, which is a registration statement filed with the SEC related to a merger transaction. It includes detailed information about securities to be registered, merger agreements, indemnification of directors and officers, and exhibits related to the merger. The presence of merger-related terms such as 'Agreement and Plan of Merger,' 'Progenitor Cell Therapy, LLC,' and 'NBS Acquisition Company LLC' indicates this filing pertains to merger activity. Form S-4 is specifically used for securities registration in connection with mergers and acquisitions. Therefore, this document is best classified under Merger & Acquisition filings.
2010-12-02 English
M&A Activity 2010
M&A Activity Classification · 100% confidence The document is a Form S-4 registration statement filed with the SEC, which is used for registering securities in connection with mergers and acquisitions. It includes detailed information about the proposed merger between NeoStem, Inc. and Progenitor Cell Therapy, LLC, including the issuance of shares and warrants, proxy statements for stockholder meetings, and descriptions of the merger agreement. The presence of the Form S-4 and the detailed merger-related content clearly indicate this is a filing related to merger and acquisition activity. Therefore, the appropriate classification is 'M&A Activity' (Code: TAR). The document length and content confirm it is not a mere announcement but a substantive filing related to the merger.
2010-11-29 English
Capital/Financing Update 2010
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 19, 2010. It announces the completion of concurrent offerings of common stock units and preferred stock units, including details about the offerings, pricing, and agents involved. It also mentions the solicitation material related to a proposed merger. The document is primarily an announcement of financing activities and related corporate events, not a full financial report or earnings release. The presence of detailed information about stock offerings and proceeds aligns with a Capital/Financing Update. The document length is about 5,391 characters, which is sufficient to contain substantive information rather than just a brief announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2010-11-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.